Skip to main content

Modulation of Wnt/β-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer.

Publication ,  Journal Article
Coombs, GS; Schmitt, AA; Canning, CA; Alok, A; Low, ICC; Banerjee, N; Kaur, S; Utomo, V; Jones, CM; Pervaiz, S; Toone, EJ; Virshup, DM
Published in: Oncogene
January 12, 2012

Using a screen for Wnt/β-catenin inhibitors, a family of 8-hydroxyquinolone derivatives with in vivo anti-cancer properties was identified. Analysis of microarray data for the lead compound N-((8-hydroxy-7-quinolinyl) (4-methylphenyl)methyl)benzamide (HQBA) using the Connectivity Map database suggested that it is an iron chelator that mimics the hypoxic response. HQBA chelates Fe(2+) with a dissociation constant of ∼10(-19) M, with much weaker binding to Fe(3+) and other transition metals. HQBA inhibited proliferation of multiple cell lines in culture, and blocked the progression of established spontaneous cancers in two distinct genetically engineered mouse models of mammary cancer, MMTV-Wnt1 and MMTV-PyMT mice, without overt toxicity. HQBA may inhibit an iron-dependent factor that regulates cell-type-specific β-catenin-driven transcription. It inhibits cancer cell proliferation independently of its effect on β-catenin signaling, as it works equally well in MMTV-PyMT tumors and diverse β-catenin-independent cell lines. HQBA is a promising specific intracellular Fe(2+) chelator with activity against spontaneous mouse mammary cancers.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Oncogene

DOI

EISSN

1476-5594

Publication Date

January 12, 2012

Volume

31

Issue

2

Start / End Page

213 / 225

Location

England

Related Subject Headings

  • beta Catenin
  • Wnt Proteins
  • Signal Transduction
  • Oncology & Carcinogenesis
  • Neoplasms
  • Mice
  • Iron Chelating Agents
  • Genetic Engineering
  • Ferrous Compounds
  • Disease Models, Animal
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Coombs, G. S., Schmitt, A. A., Canning, C. A., Alok, A., Low, I. C. C., Banerjee, N., … Virshup, D. M. (2012). Modulation of Wnt/β-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. Oncogene, 31(2), 213–225. https://doi.org/10.1038/onc.2011.228
Coombs, G. S., A. A. Schmitt, C. A. Canning, A. Alok, I. C. C. Low, N. Banerjee, S. Kaur, et al. “Modulation of Wnt/β-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer.Oncogene 31, no. 2 (January 12, 2012): 213–25. https://doi.org/10.1038/onc.2011.228.
Coombs GS, Schmitt AA, Canning CA, Alok A, Low ICC, Banerjee N, et al. Modulation of Wnt/β-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. Oncogene. 2012 Jan 12;31(2):213–25.
Coombs, G. S., et al. “Modulation of Wnt/β-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer.Oncogene, vol. 31, no. 2, Jan. 2012, pp. 213–25. Pubmed, doi:10.1038/onc.2011.228.
Coombs GS, Schmitt AA, Canning CA, Alok A, Low ICC, Banerjee N, Kaur S, Utomo V, Jones CM, Pervaiz S, Toone EJ, Virshup DM. Modulation of Wnt/β-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. Oncogene. 2012 Jan 12;31(2):213–225.

Published In

Oncogene

DOI

EISSN

1476-5594

Publication Date

January 12, 2012

Volume

31

Issue

2

Start / End Page

213 / 225

Location

England

Related Subject Headings

  • beta Catenin
  • Wnt Proteins
  • Signal Transduction
  • Oncology & Carcinogenesis
  • Neoplasms
  • Mice
  • Iron Chelating Agents
  • Genetic Engineering
  • Ferrous Compounds
  • Disease Models, Animal